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This protocol is intended to provide all 
the specialists involved with clear guidelines 
on prophylaxis and therapy, implemented in 
compliance with national and international 
literature as well as the regulations in force 
in Italy [1,2].
Issue DesCrIptIon
According to the World Health Orga-
nization, postpartum hemorrhage (PPH) 
causes about one quarter of the maternal 
deaths each year [3]. In most cases, deaths 
occur in the first 24/48 hours after delivery 
and, despite the significant improvements 
in the last three years, 66% of deaths due 
to PPH are still due to substandard care, 
according to the latest report of the Center 
IntroDuCtIon
Obstetric hemorrhage remains one of the 
major causes of maternal mortality in both 
developing and industrialized countries, 
representing a clinically and socially sig-
nificant problem. Given the critical nature 
of the problem, it is particularly important 
to effectively manage the clinical risk and 
respond aggressively at the beginning of a 
potentially dramatic event. The creation of a 
multidisciplinary team trained to act quickly 
to identify and treat the causes of hemor-
rhage according to shared protocols remains 
crucial. The availability of shared guidelines 
and of protocols, together with the organiza-
tion simulations and training, are initiatives 
of the utmost importance in the promotion 
of the safety of perinatal care.
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Postpartum hemorrhage is defined as a blood loss equal to or greater than 500 ml, which can 
occur from 24 hours to six weeks after delivery. It is a critical event with a rapid and devastating 
evolution, which can quickly lead to maternal shock and death.
Many efforts have been made to create international and multisectoral guidelines that allow 
to face an event that represents the cause of about one quarter of maternal deaths. It is crucial 
to create a team able to act promptly in accordance with shared protocols. The availability of 
shared guidelines and protocols and the organization of periodic simulations and teamwork 
training are part of the fundamental initiatives that can promote the safety of perinatal care.
The purpose of this document is to give clinicians the tools to minimize the risks associated with 
inadequate management of hemorrhagic emergency, avoiding the risk of “too little or too late” 
and giving patients maximum safety. 
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for Maternal and Child Inquiry on maternal 
mortality [4]. In addition, numerous stud-
ies have shown, in industrialized countries, 
an increase in the incidence of postpartum 
hemorrhage in recent years [5], reflecting in 
part the changes in obstetrical practice of the 
last decade (for example, the increase in the 
rate of caesarean sections or the increased 
trend toward practice of spontaneous de-
livery after caesarean section).
DefInItIon
Postpartum hemorrhage is defined as a 
blood loss equal to or greater than 500 ml, 
occurring early in the first 24 hours after 
delivery (primary postpartum hemorrhage) 
or up to six weeks postpartum (secondary 
postpartum hemorrhage), and which, if 
not identified and treated, can quickly lead 
to mother shock and death [6]. We talk 
about minor PPH if the estimated blood 
loss is between 500 and 1000 ml, but if the 
loss exceeds 1000 ml, it is defined as major 
PPH, which can be defined as controlled 
in the case of controlled blood loss, with 
impairment of maternal clinical conditions 
requiring thorough monitoring, or massive 
or persistent PPH in case of blood loss over 
1500 ml and/or signs of clinical shock and/
or transfusion of 4 or more packed red blood 
cells units, with impairment of maternal 
conditions which poses an immediate threat 
to the woman’s life.[7,8]
The pregnant woman undergoes a series of 
physiological modifications that allow her to 
withstand substantial blood loss effectively, 
and is generally a young patient with good 
cardiovascular reserve; this condition, as-
sociated with the difficulty of correctly and 
timely estimation of blood loss, can lead to 
an underestimation of the problem. It is al-
ways important to consider that significant 
blood loss, > 2000 ml, can induce a rapidly 
worsening condition, with an inexorable de-
crease in blood pressure and signs and symp-
toms of severe shock (paleness, agitation, 
oliguria, followed by mood and collapse), 
while these symptoms might be absent in 
significant but less severe blood loss.
etIology
There are many alterations that can lead 
to a PPH, but the main causes of postpar-
tum hemorrhage are: uterine atony (90%), 
cervical and/or perineal lacerations (5%), 
placental fragments retention (4%), coagu-
lation deficiencies or alterations, uterine 
inversion, uterine rupture. The morbidly 
adherent placenta, i.e. placenta accreta, in-
creta or percreta, is nowadays an important 
cause of primary hemorrhage. Previous 
uterine surgery, such as caesarean section, 
significantly increases the risk of morbidly 
adherent placenta [9]. Attention must also 
be paid to the assessment of possible clotting 
disorders and the prevention and treatment 
of anemia. According to the authors, there 
are other important risk factors to be con-
sidered: multiple pregnancy, previous PPH, 
preeclampsia, birth weight above 4000 g, 
failure to progression of the second stage, 
prolongation of the third stage of labor, epi-
siotomy [9,10].
In clinical practice, the multiple causes 
of PPH are briefly synthesized through the 
formula “4T” [11]:
1. tone (uterine atony);
2. tissue (placenta-related problems: pla-
cental, placental implants, etc.);
3. trauma (uterine rupture, lacerations, 
uterine inversion); and
4. thrombin (in relation to clotting dis-
orders).
ppH MAnAgeMent protoCol
Crucial in postpartum hemorrhage man-
agement is prophylaxis and, eventually, 
therapy of anemia or congenital clotting 
disorders, treated in collaboration with the 
hematologist.
The PPH treatment hubs are:
 y identification of the cause of PPH (4T);
 y maintenance of uterine contractility, ob-
tained through physical or pharmacologi-
cal means;
 y maintaining and supporting cardiovascu-
lar parameters with appropriate rehydra-
tion and volume expansion; maintaining 
physiological parameters, such as tem-
perature and acid/base status; and
 y prevention or therapy of hemorrhagic co-
agulopathy [1].
Management in the “golden hour” is par-
ticular important to increase patient survival. 
If possible, in patients with high hemor-
rhagic risk it is advisable the use of the cell 
separator (cell sorter with continous flow) 
and the presence of an interventional radi-
ologists in the surgery room (with portable 
digital angiography).
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A - Blood loss between 500 and 1000 
ml without signs of hemodynamic 
imbalance
 y Ask for the collaboration of all paramedi-
cal and medical figures, alert the Trans-
fusion Centre, the operating room and, 
if available, interventionist radiology. 
Contemporary involve the whole team 
ensuring the highest level of consultation.
 y Ensure two large caliber venous accesses.
 y Estimate blood loss as soon as PPH is 
diagnosed and monitor vital parameters 
every 10 minutes at least initially on ap-
propriate graphics. A graduate sterile bag 
for the evaluation of blood loss is recom-
mended.
 y Administer tranexamic acid 30 mg/kg 
[12] (ClinicalTrials.gov registration num-
ber: NCT00872469; ISRCTN76912190, 
and PACTR201007000192283).
 y Send request for availability of blood 
products to the Transfusion Centre.
 y Increase prophylactic oxytocin at thera-
peutic dose (20 IU in 500 ml saline in 
two hours). If after 20 minutes there is no 
effect, go to second line uterotonic agents 
(ergometrine: 2 vials 0.2 mg IM; sulpro-
stone: 1 vial 0.50 mg in 250 ml IV, then 
with a controlled infusion: 0.1 to 0.4 mg/h 
up to a maximum of 1.5 mg in 24 hours).
 y Effectuate a Type&Screen test, recur-
rent blood count, and coagulation tests 
(fibrinogen by Clauss method or, if avail-
able, point-of-care coagulation tests such 
as thromboelastography—TEG or rota-
tional thromboelastometry—ROTEM).
 y Avoid or correct hypothermia, acidosis, 
and desaturation.
 y Look for the origin of bleeding through 
the rule of the four T:
1. tone (evaluation and measures for ato-
ny/uterine inversion: bimanual uterine 
compression, endocavitary uterine in-
fusion by hydrostatic balloon catheter 
and uterotone drug use). In the absence 
of the hydrostatic balloon, it is possible 
to use a latex glove or a condom with 
good results, as suggested by the In-
ternational Federation of Gynecology 
and Obstetrics (FIGO) 2012 guide-
lines [13]. It is important to note that 
uterine gauze packing is not recom-
mended today;
2. tissue (exploration and evacuation of 
the uterus);
3. trauma (repairing vaginal tears, cervix, 
and/or uterine tears);
4. thrombin (evaluate and correct any 
coagulatory defect, if available, with 
Thromboelastometric/Graphic Evalu-
ation via point-of-care monitoring).
 y Targeted transfusion therapy: packed 
red blood cells to maintain hematocrit 
between 21% and 27% and hemoglobin 
between 7 and 9 g/l.
 y Evaluate fibrinogen infusion 30-50 mg/
kg or fresh frozen plasma 20-30 ml/kg if 
fibrinogen is below 200 mg/dl.
B - Blood loss greater than 1000 ml, 
hemodynamically unstable patient
Do all the operations under point A.
 y Reintegrate circulating volume with crys-
talloids or, if necessary, colloid by evalu-
ating sensory, diuresis, lactate, and excess 
bases level.
 y Maintain transfusion therapy and hemo-
static support.
 y Transfusion in the presence of PPH is 
performed by clinical indication and not 
on the basis of information derived from 
hematocrit examinations. Keep in mind 
that a packed red blood cells unit con-
tains 280 ml and increases the hemato-
crit of 2-3%:
 y it is advisable to use a 1:1:1 ratio of 
units of plasma and platelets to red 
blood cells administered, pending labo-
ratory values;
 y for the constitution of the package to 
be transfused, depending on the avail-
ability of blood products, the following 
alternatives are suggested:
 y 4 packed red blood cells units : 4 
single dose donor or industrial plas-
ma units; or
 y 4 packed red blood cells : 2 plasma 
units from apheresis;
 y platelet concentrates, it is recom-
mended to use 1 unit from apheresis 
or from buffy coat every 8 unit of 
packed red blood cells.
It is worth emphasizing the suggestion of 
the alternatives mentioned above, whose ap-
plication may vary depending on the differ-
ent realities present on the territory and the 
availability of the components and monitor-
ing tools. It is also desirable that each hos-
pital prepares a mass transfusion protocol to 
be activated in case of critical hemorrhage 
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after major bleeding. There are different 
clinical protocols depending on the dif-
ferent realities [14] and the reluctance for 
a predetermined plan of thromboprophy-
laxis reflects the awareness that women 
following intractable hemorrhage are at 
increased risk for disseminated intravas-
cular coagulopathy rather than deep vein 
thrombosis [15].
ConClusIons
In conclusion, we want to emphasize 
the importance of the rapidity of action 
and the management organization of the 
obstetric emergency. Given the dramatic 
nature of the hemorrhagic event in the 
postpartum, it is important that all women 
with known risk of uterine bleeding should 
be directed to a hospital equipped with a 
transfusion center and laboratory analysis. 
It is imperative to never overlook the as-
sessment of blood loss in order not to delay 
the beginning of care procedures, which, if 
performed at the first hour, “golden hour”, 
ensure to the woman a better chance of 
survival. It should always be kept in mind 
that one of the main causes of death for 
PPH in Western countries is the delay in 
blood transfusion. Last but not least, it is 
important to emphasize the importance 
of creating a dedicated and well-trained 
team, even through simulation scenarios, 
who can rapidly implement the previously 
shared guidelines and protocols.
Key Points
 y Given the rapid and devastating evolution of postpartum hemorrhage, it is critical to act 
quickly and aggressively in the first hour to avoid maternal shock
 y To create an efficient team, sharing management protocols and periodic simulation are of 
paramount importance
 y The multiple causes of PPH are briefly synthesized through the formula “4T”:
 y tone (uterine atony);
 y tissue (placenta-related problems: placental, placental implants, etc.);
 y trauma (uterine rupture, lacerations, uterine inversion); and
 y thrombin (in relation to clotting disorders)
 y The key points for PPH treatment are:
 y maintenance of uterine contractility;
 y maintaining and supporting cardiovascular parameters; and
 y prevention or therapy of hemorrhagic coagulopathy
with signs of hemodynamic instability and 
hypoperfusion.
 y When the result of the hemocoagula-
tory examinations is available, if the pro-
thrombin time ratio—PTTr or Interna-
tional Normalized Ratio—INR is > 1.5, 
it is necessary to infuse the plasma at the 
initial dose of 20 ml/kg with the packed 
red blood cells, up to 30 ml/kg in case 
of persistent or ingraining coagulopathy.
 y Use heating and infusion devices.
 y Always guarantee basic conditions: he-
matocrit > 21%, temperature > 34 °C, pH 
> 7.20, Ca++ > 1 mmol/l.
 y Cases nonresponders to the aforemen-
tioned therapies require a conservative 
surgical-intervention approach: compres-
sion sutures, uterine tamponation with 
hydrostatic balloon, association of devas-
cularizing sutures of uterine, ovarian or 
internal ileus arteries, selective emboliza-
tion of pelvic vessels.
 y If no response to the therapy, use recom-
binant activated clotting factor VII—rF-
VIIa (60-90 μg/kg bolus repeated within 
15-30 min) as an extrema ratio, before 
performing hysterectomy. Keep in mind 
that rFVIIa to function requires: nor-
mal pH, temperature, adequate levels of 
platelets (> 50,000/mm3), and fibrinogen 
(> 200 mg/dl).
 y If no response occurs, proceed to subtotal 
or total hysterectomy.
 y There is no agreement in the literature on 
the use and choice of thromboprophylaxis 
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